Introduction Venous thromboembolism (VTE) is a condition that annually occurs in approximately 1% of the world's population. Patients who have already had a VTE are at elevated risk for a recurrent VTE. Recurrent events increase the risk of long-term sequelae and can be fatal. Adequate secondary prophylaxis is thus needed to prevent such events. Patients with VTE are often prone to bleeding, and pharmacological prophylaxis exacerbates bleeding risk. Expert opinions on the optimum duration of secondary prophylaxis in VTE still vary substantially. The existence of treatment guidelines has not led to uniformity of VTE secondary prophylaxis strategies, which means that physicians still adhere to individual risk calculi in determining treatment ...
Objectives: Secondary prevention of venous thromboembolism (VTE) remains a topical and contentious p...
Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and seco...
International audienceProximal deep venous thrombosis and pulmonary embolism should be treated for a...
Introduction Venous thromboembolism (VTE) is a condition that annually occurs in approximately 1% of...
INTRODUCTION: Venous thromboembolism (VTE) carries a considerable risk of recurrence and anticoagula...
Introduction Venous thromboembolism (VTE) carries a considerable risk of recurrence and anticoagulan...
International audienceRECURRENT THROMBOSIS VERSUS ANTICOAGULANT-RELATED BLEEDING: The optimal durati...
International audienceThe optimal duration of anticoagulation after venous thromboembolism (VTE) is ...
International audienceDetermination of the optimal duration of anticoagulant treatment for venous th...
The risk of recurrent venous thromboembolism (VTE) approaches 40% of all patients after 10 years of ...
The risk of recurrent venous thromboembolism (VTE) approaches 40 per cent of all patients after 10 y...
Randomized controlled trials have shown that patients with venous thromboembolism benefit from a min...
Venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (P...
Once anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years after...
BackgroundPatients with unprovoked (i.e., without the presence of apparent transient risk factors su...
Objectives: Secondary prevention of venous thromboembolism (VTE) remains a topical and contentious p...
Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and seco...
International audienceProximal deep venous thrombosis and pulmonary embolism should be treated for a...
Introduction Venous thromboembolism (VTE) is a condition that annually occurs in approximately 1% of...
INTRODUCTION: Venous thromboembolism (VTE) carries a considerable risk of recurrence and anticoagula...
Introduction Venous thromboembolism (VTE) carries a considerable risk of recurrence and anticoagulan...
International audienceRECURRENT THROMBOSIS VERSUS ANTICOAGULANT-RELATED BLEEDING: The optimal durati...
International audienceThe optimal duration of anticoagulation after venous thromboembolism (VTE) is ...
International audienceDetermination of the optimal duration of anticoagulant treatment for venous th...
The risk of recurrent venous thromboembolism (VTE) approaches 40% of all patients after 10 years of ...
The risk of recurrent venous thromboembolism (VTE) approaches 40 per cent of all patients after 10 y...
Randomized controlled trials have shown that patients with venous thromboembolism benefit from a min...
Venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (P...
Once anticoagulation is stopped, the risk of recurrent venous thromboembolism (VTE) over years after...
BackgroundPatients with unprovoked (i.e., without the presence of apparent transient risk factors su...
Objectives: Secondary prevention of venous thromboembolism (VTE) remains a topical and contentious p...
Clinical practice guidelines currently suggest extended anticoagulation therapy for primary and seco...
International audienceProximal deep venous thrombosis and pulmonary embolism should be treated for a...